Status:
RECRUITING
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
Lead Sponsor:
Children's Hospital Los Angeles
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Social Anxiety Disorder
Eligibility:
All Genders
16-22 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to identify the circuit activations by very brief exposure (VBE) among youth with social anxiety disorder (SAD) in order to develop a novel intervention for those wi...
Eligibility Criteria
Inclusion
- Patient Population
- Males and females aged 16-22. This age range corresponds with our prior studies of very brief exposure (VBE) in Specific Phobia and will include older adolescents while minimizing potential developmental effects on circuit activation.
- Youth with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of Social Anxiety Disorder (SAD) on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Computerized version (K-SADS-COMP) for youth ages 16-17, or the computerized version of Structured Clinical Interview for the DSM-5 (NetSCID) for youth ages 18+.
- Healthy Population
- • Male and female youth aged 16-22.
- Parents • Parent/caregiver of all ages, no restrictions who are fluent in either English or Spanish.
Exclusion
- Patient Population
- Primary language other than English or Spanish.
- Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior)
- Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.
- Current psychoactive medication.
- Lifetime diagnosis of: obsessive-compulsive disorder (OCD), psychotic, bipolar, autism spectrum disorder, intellectual disability on the KSADS-COMP or NetSCID.
- Any serious neurological or medical conditions (e.g., Lupus, cancer, human immunodeficiency virus positive (HIV+)) as reported by potential participants.
- Current Post-Traumatic Stress Disorder (PTSD) diagnosis.
- Current severe substance abuse (except tobacco/nicotine).
- Pregnancy, as determined by the participant's self-report prior to the magnetic resonance imaging (MRI) scan.
- Healthy Population
- Primary language other than English or Spanish.
- Lifetime disorders: any anxiety disorders, OCD, psychotic, bipolar, autism spectrum disorder, intellectual disability; any psychiatric disorder in the past 2 years
- Current depression disorder.
- Active psychiatric disorder in the past 2 years.
- Serious neurological or medical conditions.
- Current psychoactive medication.
- Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.
- Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior).
- Pregnancy, as determined by the participant's self-report prior to the MRI scan.
- Parents • Primary language other than English or Spanish.
Key Trial Info
Start Date :
August 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06526260
Start Date
August 14 2024
End Date
July 1 2026
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027